This page shows the latest Simponi news and features for those working in and with pharma, biotech and healthcare.
to compete strongly against well-established ulcerative colitis drugs such as Humira and Johnson &Johnson’s Simponi (golimumab).
Regardless, Caruso said that J&J's immunology franchise remains strong thanks to newer entrants such as Stelara (ustekinumab) and Simponi (golimumab) and with 10 new products filed with blockbuster potential ... Simponi grew 30% to $390m in the quarter,
NICE's other new final draft recommendations for severe RA also include AbbVie's Humira (adalimumab), Pfizer's Enbrel (etanercept), UCB Pharma's Cimzia (certolizumab pegol), Merck Sharp &Dohme's Simponi
infliximab), AbbVie's Humira (adalimumab) and Johnson &Johnson's Simponi (golimumab).
J&J saw strong growth from its broad immunological drug range that includes Remicade (infliximab) and Simponi (golimumab), which both treat rheumatoid arthritis as well as other auto-inflammatory disorders, and
More from news
Approximately 6 fully matching, plus 31 partially matching documents found.
The two infliximab biosimilars are also included in the cost-effectiveness watchdog's ongoing appraisals of TNF-alpha inhibitors for ankylosing spondylitis and its review of Humira, Enbrel, Remicade, Cimzia, Simponi,
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
44 7595 003744. Address:. Greencoat House. Francis Street. London. SW1P 1DH. United Kingdom.
Client: Merck Sharp &Dohme. Therapy area: Musculo-skeletal Disorders. View the PMHub profile for: VCCP Health.
leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from biosimilar
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...